San Francisco, Calif. – Eli Lilly and Company has decided to stop producing Humulin U and Humulin L Insulins. According to a letter to health care providers, use of these longer-acting insulins has declined by more than 70% over the past five years due to newer insulin therapies. The company estimates less than 2% of diabetes patients in the U.S. will be affected by this discontinuation.
To view the letter to health care professionals, please visit: http://www.fda.gov/cder/drug/shortages/HumulinDr.pdf
Contact Suvarna Bhatt at sbhatt@biospace.com.
